

GENENT.093A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vanessa Hsei et al.

Appl. No. : 09/234,182

Filed : January 20, 1999

For : ANTIBODY FRAGMENT
POLYMER CONJUGATES
AND HUMANIZED ANTI-IL-8
MONOCLONAL ANTIBODIES

) Group Art Unit 1644

)
) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327,
) Arlington, VA 22202, on

) February 22, 2002

) (Date)

) Ginger K. Dreger Reg. No. 33,055

Examiner : Dibrino, M.

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

The present response is filed concurrently with filing of a Request for Continued Examination of the above-identified patent application. Please enter the following amendments, and consider the following arguments.

In the Claims:

Please amend claim 1 to read as follows:

1. (Twice amended) A conjugate of a single antibody fragment covalently attached to a single polyethylene glycol (PEG) molecule, wherein the antibody fragment is a Fab' comprising (1) a first chain that is either a light chain or a heavy chain and (2) a first opposite chain that is either a heavy chain opposite the first light chain or a light chain opposite the first heavy chain, wherein the PEG molecule is covalently attached to a first cysteine residue in the first chain that would ordinarily form a disulfide bridge with a second cysteine residue in the first opposite chain, wherein the disulfide bridge is avoided by substitution of another amino acid

RECEIVED
MAR 11 2002
TECH CENTER 1600 2300